Computer Applied Sciences, Certificates Of Achievement

Topics lined in this Cybersecurity Certificate program embody penetration testing, ethical hacking, security analyst, forensic investigator, and secure internet programming. This certificate prepares college students to work in the field of local and broad space networks. Students study network connectivity ideas, requirements, and protocols used to connect Computer community devices. In addition, the curriculum covers use of Cisco IOS software in a lab environment and set up of networking hardware and software in routers and switches utilizing state-of-the-art Cisco networking equipment. As a Cisco Network Academy, all course supplies, together with checks, are developed and maintained by Cisco.

Some folks can compensate for top charges of enter errors by using spell checkers, thesauruses, and grammar checkers. In addition, word prediction programs have been used successfully by students with learning disabilities. Similarly, macro software program which expands abbreviations can scale back the necessity to memorize keyboard instructions and can ease the … Read More

Cassava Sciences Doubles on Progress With Alzheimer’s Treatment

Shares of Cassava Sciences more than doubled on Tuesday after the drugmaker reported progress in a study of its Alzheimer’s treatment candidate.



a close up of a hand: Cassava Sciences Doubles on Progress With Alzheimer's Treatment


© TheStreet
Cassava Sciences Doubles on Progress With Alzheimer’s Treatment

The Austin company reported results from a study of simufilam, which was associated with improved patient cognition and behavior scores after six months of treatment.

“We would have been satisfied to show simufilam stabilizes cognition in patients over six months, President and Chief Executive Remi Barbier said in a statement.

“An improvement in cognition and behavior tells us this drug candidate has potential to provide lasting treatment effects for people living with Alzheimer’s disease.”

Cassava shares at last check were trading at $49.67. They’d closed Monday trading at $22.99. Last May the stock touched a 52-week low at $1.63.

The company reported no serious drug-related adverse events during the six-month treatment regimen.

The clinical study was funded

Read More